[1] NG S C,TANG W,CHING J Y,et al.Incidence and phenotype of inflammatory bowel disease based on results from the Asia-pacific Crohn's and colitis epidemiology study[J].Gastroenterology,2013,145(1):158-165.
[2] NG S C,LEUNG W K,SHI H Y,et al.Epidemiology of inflammatory bowel disease from 1981 to 2014:Results from a territory-wide population-based registry in Hong Kong[J].Inflamm Bowel Dis,2016,22(8):1954-1960.
[3] LOUIS E,COLLARD A,OGER A F,et al.Behaviour of Crohn's disease according to the Vienna classification:changing pattern over the course of the disease[J].Gut,2001,49(6):777-782.
[4] COSENS J,NION-LARMURIER I,BEAUGERIE L,et al.Impact of the increasing use of immunosuppressants in Crohn's disease on the need for intestinal surgery[J].Gut,2005,54(2):237-241.
[5] KRISHNA M,NARANG H.The complexity of mitogen-activated protein kinases (MAPKs) made simple[J].Cell Mol Life Sci,2008,65(22):3525-3544.
[6] SHAUL Y D,SEGER R.The MEK/ERK cascade:from signaling specificity to diverse functions[J].Biochim Biophys Acta,2007,1773(8):1213-1226.
[7] RAMAN M,CHEN W,COBB M H.Differential regulation and properties of MAPKs[J].Oncogene,2007,26(22):3100-3112.
[8] PIMIENTA G,PASCUAL J.Canonical and alternative MAPK signaling[J].Cell Cycle,2007,6(21):2628-2632.
[9] LATELLA G,DI G J,FLATI V,et al.Mechanisms of initiation and progression of intestinal fibrosis in IBD[J].Scand J Gastroenterol,2015,50(1):53-65.
[10] WELLS R G.The role of matrix stiffness in regulating cell behavior[J].Hepatology,2008,47(4):1394-1400.
[11] LATELLA G,ROGLER G,BAMIAS G,et al.Results of the 4th scientific workshop of the ECCO(Ⅰ):pathophysiology of intestinal fibrosis in IBD[J].J Crohns Colitis,2014,8(10):1147-1165.
[12] FIOCCHI C,LUND P K.Themes in fibrosis and gastrointestinal inflammation[J].Am J Physiol Gastrointest Liver Physiol,2011,300(5):G677-683.
[13] RIEDER F,FIOCCHI C.Mechanisms of tissue remodeling in inflammatory bowel disease[J].Digest Dis,2013,31(2):186-193.
[14] SPECA S,GIUSTI I,RIEDER F,et al.Cellular and molecular mechanisms of intestinal fibrosis[J].World J Gastroenterol,2012,18(28):3635-3661.
[15] PAGES G,LENORMAND P,L'ALLEMAIN G,et al.Mitogen-activated protein kinases p42 MAPK and p44 MAPK are required for fibroblast proliferation[J].Proc Natl Acad Sci U S A,1993,90(18):8319-8323.
[16] SCHMIDT A,WENZEL D,THOREY I,et al.Endostatin influences endothelial morphology via the activated ERK1/2-kinase endothelial morphology and signal transduction[J].Microvasc Res,2006,71(3):152-162.
[17] BHATTACHARJEE N,BARMA S,KONWAR N,et al.Mechanistic insight of diabetic nephropathy and its pharmacotherapeutic targets:An update[J].Eur J Pharmacol,2016,791:8-24.
[18] GRYNBERG K,MA F Y,NIKOLIC-PATERSON D J.The JNK signaling pathway in renal fibrosis[J].Front Physiol,2017,8:829.
[19] LI R,WANG Y,LIU Y,et al.Curcumin inhibits transforming growth factor-beta1-induced EMT via PPARgamma pathway,not Smad pathway in renal tubular epithelial cells[J].PLoS One,2013,8(3):e58848.
[20] 陈莲香,舒建昌.PDGF与肝纤维化关系的研究新进展[J].胃肠病学和肝病学杂志,2011,20(1):95-98.
[21] LI Q,LIU X,WEI J.Ageing related periostin expression increase from cardiac fibroblasts promotes cardiomyocytes senescent[J].Biochem Biophys Res Commun,2014,452(3):497-502.
[22] WYNN T A.Common and unique mechanisms regulate fibrosis in various fibroproliferative diseases[J].J Clin Invest,2007,117(3):524-529.
[23] WICK G,GRUNDTMAN C,MAYERL C,et al.The immunology of fibrosis[J].Annu Rev Immunol,2013,31:107-135.
[24] SAINI S,LIU T,YOO J.TNF-alpha stimulates colonic myofibroblast migration via COX-2 and Hsp27[J].J Surg Res,2016,204(1):145-152.
[25] MEDIA C,SANTOS-MARTINEZ M J,SANTANA A,et al.Transforming growth factor-beta type 1 receptor(ALK5) and Smad proteins mediate TIMP-1 and collagen synthesis in experimental intestinal fibrosis[J].J Pathol,2011,224(4):461-472.
[26] INOUE R,JENSEN L J,SHI J,et al.Transient receptor potential channels in cardiovascular function and disease[J].Circ Res,2006,99(2):119-131.
[27] NISHIDA M,ONOHARA N,SATO Y,et al.Galpha12/13-mediated up-regulation of TRPC6 negatively regulates endothelin-1-induced cardiac myofibroblast formation and collagen synthesis through nuclear factor of activated T cells activation[J].J Biol Chem,2007,282(32):23117-23128.
[28] KURAHARA L H,SUMIYOSHI M,AOYAGI K,et al.Intestinal myofibroblast TRPC6 channel may contribute to stenotic fibrosis in Crohn's disease[J].Inflamm Bowel Dis,2015,21(3):496-506.
[29] HOLVOET T,DEVRIESE S,CASTERMANS K,et al.Treatment of intestinal fibrosis in experimental inflammatory bowel disease by the pleiotropic actions of a local Rho kinase inhibitor[J].Gastroenterology,2017,153(4):1054-1067.
[30] LAWRANCE I C,MAXWELL L,DOE W.Altered response of intestinal mucosal fibroblasts to profibrogenic cytokines in inflammatory bowel disease[J].Inflamm Bowel Dis,2001,7(3):226-236.
[31] ZIMMERMANN E M,LI L,HOU Y T,et al.Insulin-like growth factor Ⅰ and insulin-like growth factor binding protein 5 in Crohn's disease[J].Am J Physiol Gastrointest Liver Physiol,2001,280(5):G1022-1029.
[32] JONES J I,GOCKERMAN A,BUSBY W H,et al.Extracellular matrix contains insulin-like growth factor binding protein-5:potentiation of the effects of IGF-Ⅰ[J].J Cell Biol,1993,121(3):679-687.
[33] XIN X,HOU Y T,LI L,et al.IGF-Ⅰ increases IGFBP-5 and collagen alpha1(Ⅰ) mRNAs by the MAPK pathway in rat intestinal smooth muscle cells[J].Am J Physiol Gastrointest Liver Physiol,2004,286(5):G777-783.
[34] RIEDER F,FIOCCHI C,ROGLER G.Mechanisms,management,and treatment of fibrosis in patients with inflammatory bowel diseases[J].Gastroenterology,2017,152(2):340-350.
[35] 孙纲,隋欣,高建军.肠梗阻导管治疗克罗恩病性肠梗阻3例[J].现代医学,2013,41(9):678-679.
[36] LIM A K,NIKOLIC-PATERSON D J,MA F Y,et al.Role of MKK3-p38 MAPK signalling in the development of type 2 diabetes and renal injury in obese db/db mice[J].Diabetologia,2009,52(2):347-358.
[37] 吉其舰,许铁.积雪草苷对博莱霉素诱导的大鼠肺纤维化的保护作用[J].现代医学,2014,42(11):1304-1309. |
